Nasdaq · CIK 0001622229
COGT Cogent Biosciences, Inc.
Insider trading from SEC Form 4. Last filing 8 d ago. Close $31.00 on Oct 9, 2026, +119% from the 52-week low and -28% from the high.
Cogent Biosciences, Inc. (COGT) has 40 SEC Form 4 filings on file from 13 insiders, the latest filed on Oct 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
8 open-market trades have been scored at COGT. The newest: Fairmount Funds Management LLC (director) sold $243M of stock on Mar 31, 2026, filed Mar 31, 2026, scored 60 (notable). 4 insiders sold within 14 days of each other around Dec 26, 2025.
COGT closed at $31.00 on Oct 9, 2026, 119% above its 52-week low and 28% below its 52-week high.
6 Form 144 notices of planned sales are on file, the latest filed Mar 31, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cogent Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | Fairmount Funds Management LLC director sell | $243M 7,000,000 shares | -56% | +857% from low-9% from high | |
| 50Moderate | Fairmount Funds Management LLC director sell | $127M 3,500,000 shares | -39% | +883% from low-6% from high | |
| 65Notable | John Edward Robinson Chief Scientific Officer sell | $3.5M 90,000 shares | -39% | +867% from low-8% from high | |
| 65Notable | Jessica Sachs Chief Medical Officer sell | $3.2M 82,642 shares | -38% | +867% from low-8% from high | |
| 72Notable | John L. Green Chief Financial Officer sell | $3.0M 77,000 shares | -37% | +867% from low-8% from high | |
| 65Notable | Evan Kearns Chief Legal Officer sell | $2.5M 65,000 shares | -37% | +867% from low-8% from high | |
| 46Moderate | Fairmount Funds Management LLC director buy | $25M 2,777,777 shares | +45% | +170% from low-12% from high | |
| 40Moderate | Cole Pinnow Chief Commercial Officer buy | $332k 43,750 shares | +2085% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 31, 2026 | Fairmount Healthcare Fund II L.P. Director | 7,000,000 4.31% of outstanding | $243M | Mar 31, 2026 | $127M |
| Jan 22, 2026 | Fairmount Healthcare Fund II L.P. Director | 3,500,000 2.28% of outstanding | $127M | Jan 22, 2026 | none |
| Dec 29, 2025 | EVAN D KEARNS Officer | 65,000 0.05% of outstanding | $2.5M | Dec 26, 2025 | none |
| Dec 29, 2025 | JOHN GREEN Officer | 77,000 0.05% of outstanding | $3.0M | Dec 26, 2025 | none |
| Dec 29, 2025 | JOHN ROBINSON Officer | 90,000 0.06% of outstanding | $3.5M | Dec 26, 2025 | none |
| Dec 29, 2025 | JESSICA SACHS Officer | 82,642 0.06% of outstanding | $3.2M | Dec 26, 2025 | none |
Transactions
The newest 50 of 61 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Karen Jean Ferrante director | AGrant or award Stock Option (Right to Buy)derivative | +759 | $0.00 | $0 | 759 | 8 d ago |
| Jun 9, 2026 | Peter Evan Harwin director | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| Jun 9, 2026 | Karen Jean Ferrante director | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| Jun 9, 2026 | Christopher W. Cain director | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| Jun 9, 2026 | Todd Shegog director | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| Jun 9, 2026 | Arlene Morris director | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| Jun 9, 2026 | Matthew Ros director | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| May 19, 2026 | Andrew R Robbins President and CEO | GGift Common Stock | -160,000 | $0.00 | $0 | 497,503 | May 21, 2026 |
| May 19, 2026 | Andrew R Robbins President and CEO | GGift Common Stockindirect: By trust | +160,000 | $0.00 | $0 | 160,000 | May 21, 2026 |
| Apr 1, 2026 | Karen Jean Ferrante director | AGrant or award Stock Option (Right to Buy)derivative | +686 | $0.00 | $0 | 686 | Apr 3, 2026 |
| Mar 31, 2026 | Fairmount Funds Management LLC director | CConversion Common Stockindirect: Fairmount Healthcare Fund II LP | +7,000,000 | - | - | 12,503,418 | Mar 31, 2026 |
| Mar 31, 2026 | Fairmount Funds Management LLC director | SOpen-market sale Common Stockindirect: Fairmount Healthcare Fund II LP | -7,000,000 | $34.66 | $243M | 5,503,418 | Mar 31, 2026 |
| Mar 31, 2026 | Fairmount Funds Management LLC director | CConversion Series A Convertible Preferred Stockderivativeindirect: Fairmount Healthcare Fund II LP | -28,000 | $0.00 | $0 | 39,414 | Mar 31, 2026 |
| Jan 22, 2026 | Fairmount Funds Management LLC director | SOpen-market sale Common Stockindirect: Fairmount Healthcare Fund II LP | -3,500,000 | $36.40 | $127M | 5,503,418 | Jan 22, 2026 |
| Jan 1, 2026 | Karen Jean Ferrante director | AGrant or award Stock Option (Right to Buy)derivative | +643 | $0.00 | $0 | 643 | Jan 5, 2026 |
| Dec 26, 2025 | Evan Kearns Chief Legal Officer | SOpen-market sale Common Stock | -65,000 | $38.70 | $2.5M | 109,398 | Dec 30, 2025 |
| Dec 26, 2025 | John Edward Robinson Chief Scientific Officer | SOpen-market sale Common Stock | -90,000 | $38.74 | $3.5M | 140,002 | Dec 30, 2025 |
| Dec 26, 2025 | Jessica Sachs Chief Medical Officer | SOpen-market sale Common Stock | -82,642 | $38.70 | $3.2M | 133,938 | Dec 30, 2025 |
| Dec 26, 2025 | John L. Green Chief Financial Officer | SOpen-market sale Common Stock | -77,000 | $38.68 | $3.0M | 131,834 | Dec 30, 2025 |
| Dec 17, 2025 | Cole Pinnow Chief Commercial Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 97,450 | Dec 19, 2025 |
| Dec 17, 2025 | John L. Green Chief Financial Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 53,841 | Dec 19, 2025 |
| Dec 17, 2025 | Andrew R Robbins President and CEO | AGrant or award Common Stock | +185,000 | $0.00 | $0 | 185,000 | Dec 19, 2025 |
| Dec 17, 2025 | John Edward Robinson Chief Scientific Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 50,000 | Dec 19, 2025 |
| Dec 17, 2025 | Evan Kearns Chief Legal Officer | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 40,000 | Dec 19, 2025 |
| Dec 17, 2025 | Jessica Sachs Chief Medical Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 51,296 | Dec 19, 2025 |
| Dec 17, 2025 | Cole Pinnow Chief Commercial Officer | AGrant or award Common Stock | +214,000 | $0.00 | $0 | 311,450 | Dec 19, 2025 |
| Dec 17, 2025 | Andrew R Robbins President and CEO | AGrant or award Common Stock | +840,000 | $0.00 | $0 | 1,025,000 | Dec 19, 2025 |
| Dec 17, 2025 | John Edward Robinson Chief Scientific Officer | AGrant or award Common Stock | +320,000 | $0.00 | $0 | 370,000 | Dec 19, 2025 |
| Dec 17, 2025 | John L. Green Chief Financial Officer | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 353,841 | Dec 19, 2025 |
| Dec 17, 2025 | Evan Kearns Chief Legal Officer | AGrant or award Common Stock | +260,000 | $0.00 | $0 | 300,000 | Dec 19, 2025 |
| Dec 17, 2025 | Jessica Sachs Chief Medical Officer | AGrant or award Common Stock | +320,000 | $0.00 | $0 | 371,296 | Dec 19, 2025 |
| Dec 17, 2025 | Cole Pinnow Chief Commercial Officer | FTax withholding Common Stock | -94,800 | $39.45 | $3.7M | 216,650 | Dec 19, 2025 |
| Dec 17, 2025 | Andrew R Robbins President and CEO | FTax withholding Common Stock | -367,497 | $39.45 | $14M | 657,503 | Dec 19, 2025 |
| Dec 17, 2025 | John Edward Robinson Chief Scientific Officer | FTax withholding Common Stock | -139,998 | $39.45 | $5.5M | 230,002 | Dec 19, 2025 |
| Dec 17, 2025 | John L. Green Chief Financial Officer | FTax withholding Common Stock | -145,007 | $39.45 | $5.7M | 208,834 | Dec 19, 2025 |
| Dec 17, 2025 | Evan Kearns Chief Legal Officer | FTax withholding Common Stock | -125,602 | $39.45 | $5.0M | 174,398 | Dec 19, 2025 |
| Dec 17, 2025 | Jessica Sachs Chief Medical Officer | FTax withholding Common Stock | -154,716 | $39.45 | $6.1M | 216,580 | Dec 19, 2025 |
| Dec 17, 2025 | Cole Pinnow Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Dec 19, 2025 |
| Dec 17, 2025 | Andrew R Robbins President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +245,000 | $0.00 | $0 | 245,000 | Dec 19, 2025 |
| Dec 17, 2025 | John Edward Robinson Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Dec 19, 2025 |
| Dec 17, 2025 | John L. Green Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Dec 19, 2025 |
| Dec 17, 2025 | Evan Kearns Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Dec 19, 2025 |
| Dec 17, 2025 | Jessica Sachs Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Dec 19, 2025 |
| Oct 1, 2025 | Karen Jean Ferrante director | AGrant or award Stock Option (Right to Buy)derivative | +1,642 | $0.00 | $0 | 1,642 | Oct 3, 2025 |
| Jul 10, 2025 | Fairmount Funds Management LLC director | POpen-market purchase Common Stockindirect: Fairmount Healthcare Fund II LP | +2,777,777 | $9.00 | $25M | 9,003,418 | Jul 14, 2025 |
| Jul 1, 2025 | Karen Jean Ferrante director | AGrant or award Stock Option (Right to Buy)derivative | +3,314 | $0.00 | $0 | 3,314 | Jul 2, 2025 |
| Jun 4, 2025 | Christopher W. Cain director | AGrant or award Stock Option (Right to Buy)derivative | +44,700 | $0.00 | $0 | 44,700 | Jun 5, 2025 |
| Jun 4, 2025 | Arlene Morris director | AGrant or award Stock Option (Right to Buy)derivative | +44,700 | $0.00 | $0 | 44,700 | Jun 5, 2025 |
| Jun 4, 2025 | Peter Evan Harwin director | AGrant or award Stock Option (Right to Buy)derivative | +44,700 | $0.00 | $0 | 44,700 | Jun 5, 2025 |
| Jun 4, 2025 | Todd Shegog director | AGrant or award Stock Option (Right to Buy)derivative | +44,700 | $0.00 | $0 | 44,700 | Jun 5, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Christopher W. Caindirector
- Fairmount Funds Management LLCdirector, owner
- Karen Jean Ferrantedirector
- John L. GreenChief Financial Officer
- Peter Evan Harwindirector, owner
- Evan KearnsChief Legal Officer
- Arlene Morrisdirector
- Cole PinnowChief Commercial Officer
- Andrew R RobbinsPresident and CEO
- John Edward RobinsonChief Scientific Officer
- Matthew Rosdirector, coo, officer
- Jessica SachsChief Medical Officer
- Todd Shegogdirector
Questions about COGT
Answered from the filings on this page, as of the latest one.
Are insiders buying COGT?
No. In the last 90 days no insider at Cogent Biosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade COGT on the open market?
Fairmount Funds Management LLC (director) sold $243M of COGT on Mar 31, 2026 and filed the Form 4 on Mar 31, 2026. InsiderTell scored 60 (notable).
How many insiders file Form 4 at Cogent Biosciences, Inc.?
13 people have filed a Form 4 at Cogent Biosciences, Inc., among them Christopher W. Cain (director), Fairmount Funds Management LLC (director and 10% owner), Karen Jean Ferrante (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.